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Abstract
S-nitrosothiol-modified chitosan oligosaccharides were synthesized by reaction with 2-
iminothiolane hydrochloride and 3-acetamido-4,4-dimethylthietan-2-one, followed by the thiol 
nitrosation. The resulting nitric oxide (NO)-releasing chitosan oligosaccharides stored ~0.3 μmol 
NO/mg chitosan. Both the chemical structure of the nitrosothiol (i.e., primary and tertiary) and the 
use of ascorbic acid as a trigger for NO donor decomposition were used to control the NO-release 
kinetics. With ascorbic acid, the S-nitrosothiol-modified chitosan oligosaccharides elicited a 4-log 
reduction in Pseudomonas aeruginosa (P. aeruginosa) viability. Confocal microscopy indicated that 
the primary S-nitrosothiol-modified chitosan oligosaccharides associated more with the bacteria 
relative to the tertiary S-nitrosothiol system. The primary S-nitrosothiol-modified chitosan 
oligosaccharides elicited minimal toxicity towards L929 mouse fibroblast cells at the 
concentration necessary for a 4-log reduction in bacterial viability, further demonstrating the 
potential of S-nitrosothiol-modified chitosan oligosaccharides as NO-release therapeutics.
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Introduction
Bacterial infections are a tremendous challenge to human health.[1] Increased resistance to 
antibiotics has created a demand for alternative antibacterial therapeutics.[1–3] The 
endogenously-produced diatomic free radical nitric oxide (NO), plays a key role in our 
body’s nature immune response to pathogens.[4–6] Both NO and its reactive byproducts 
(e.g., peroxynitrite and dinitrogen trioxide) exert significant oxidative and nitrosative stress 
on bacteria to facilitate their eradication.[6] As such, macromolecular NO-releasing 
scaffolds have been widely developed for use in a number of biomedical applications, many 
related to pathogen killing.[7–17] The NO delivery efficiency and antibacterial efficacy are 
greatly dependent on the morphology, size and chemical composition of the NO donor 
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scaffold.[9, 10, 18] Chitosan-based materials are particularly attractive due to their 
biocompatibility, biodegradability and high primary amine precursor content for NO donor 
modification (i.e., N-diazeniumdiolate).[19–24] Wan et al. reported the synthesis of chitosan 
polysaccharides as scaffolds for NO storage by reaction of primary amines with NO to form 
N-diazeniudmiolate NO donors.[25] Due to the instability of primary amine-derived N-
diazeniumdiolate NO donors,[26] these materials were characterized by low NO storage 
(i.e., lower than 0.2 μmol/mg) and short NO-release duration (~1 h).[25] To prepare NO-
releasing chitosan scaffolds with extended release properties, folate-grafted chitosan was 
synthesized by the condensation of folic acid with primary amines on chitosan 
polysaccharides.[27] The resulting secondary amines were reacted with NO to form 
secondary amine-derived N-diazeniumdiolates. As expected, the NO release was extended to 
>10 h due to enhanced stability of the secondary amine-derived N-diazeniumdiolate NO 
donors.[26] However, total NO storage of the folate-grafted chitosan was low (i.e., <80 
nmol/mg),[27] necessitating large dose of chitosan for complete killing of certain bacterial. 
Secondary amine-functionalized chitosan oligosaccharides were thus prepared by grafting 2- 
methyl aziridine from the primary amines of the chitosan oligosaccharides. The solubility of 
the chitosan oligosaccharides in basic solutions allowed more efficient N-diazeniumdiolate 
NO donor formation, greater total NO storage (e.g., ~0.87 μmol/mg), and extended release 
duration (e.g., ~20 h).[28]
In contrast to their N-diazeniumdiolate counterparts, S-nitrosothiol NO donors can 
decompose through multiple mechanisms including photo and thermal irradiation, 
transnitrosation, and chemical reduction.[29, 30] Ascorbic acid or vitamin C is a natural 
antioxidant present in the body, which has demonstrated synergistic antibacterial efficacy 
with antibiotics including chloramphenicol, kanamycin, streptomycin, and tetracycline 
against P. aeruginosa.[31] As a reducing agent, ascorbic acid allowed for triggered S-
nitrosothiols decomposition and subsequent NO release.[32] To date, no study has examined 
the ability to prepare S-nitrosothiol-modified chitosan or evaluate the potential synergistic 
antibacterial efficacy of such materials with ascorbic acid as a trigger for NO release.
EXPERIMENTAL
Materials and Methods
Medium molecular weight chitosan, fetal bovine serum (FBS), Dulbecco’s Modified Eagle’s 
Medium (DMEM), phenazine methosulfate (PMS), 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS), trypsin, 
diethylene triamine pentaacetic acid (DTPA), phosphate buffered saline (PBS) used for cell 
culture, and penicillin streptomycin (PS) solution (10,000 u/mL penicillin, 10,000 μg/mL 
streptomycin) were purchased from the Aldrich Chemical Company (Milwaukee, WI). 
Pseudomonas aeruginosa (ATCC #19143) was obtained from the American Type Culture 
Collection (Manassas, VA). Trypic soy broth (TSB) and Tryptic soy agar (TSA) were 
purchased from Becton, Dickinson, and Company (Franklin Lakes, NJ). L929 mouse 
fibroblasts (ATCC #CCL-1) were obtained from the University of North Carolina Tissue 
Culture Facility (Chapel Hill, NC). Distilled water was purified with a Millipore Milli-Q 
Gradient A-10 water purification system (Bedford, MA). Common laboratory salts and 
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solvents were purchased from Fisher Scientific (Pittsburgh, PA). Unless noted otherwise, all 
materials were used as received without further purification. 1H nuclear magnetic resonance 
(NMR) spectra were recorded on a 400 MHz Bruker instrument. Elemental analysis was 
carried out using an inductively coupled plasma (ICP) optical emission spectrometer 
(Prodigy High Dispersion ICP-OES, Teledyne Leeman Labs, Hudson, NH). The emission 
intensity at 324.75 nm was monitored for copper. Standard addition of a copper reference 
standard (TraceCERT®, Sigma-Aldrich, St. Louis, MO) was employed to determine the 
concentration of dissolved copper in PBS buffer.
Synthesis of Chitosan Oligosaccharides
Chitosan oligosaccharides were prepared by oxidative degradation using hydrogen peroxide.
[33] Medium molecular weight chitosan (2.5 g) was suspended in a hydrogen peroxide 
solution (15 wt%) under stirring for 1 h at 85 °C. Following removal of undissolved chitosan 
by filtration, chitosan oligosaccharides were precipitated out of solution using acetone. The 
precipitate was collected by centrifugation and washed twice with ethanol before drying 
under vacuum at room temperature. The viscosity of the chitosan oligosaccharides was 
measured in a solution of sodium chloride (0.20 M) and acetic acid (0.10 M) at 25 °C using 
an Ubbleohde capillary viscometer. The molecular weight of the chitosan was determined 
using the classic Mark-Houwink equation ([η]=1.81×10−3 M0.93).[34] Elemental analysis 
was used to characterize the nitrogen content of the resulting chitosan oligosaccharides 
using a PerkinElmer CHN/S O Elemental Analyzer Series 2400 (Waltham, MA) instrument.
Synthesis of Thiol-Modified Chitosan Oligosaccharides
(Scheme 1) Primary thiol-modified chitosan oligosaccharides (Chitosan-TBA) (2) were 
synthesized according to a previous report.[35] Briefly, chitosan oligosaccharides (25 mg) 
were dissolved in aqueous solution (1 mL) at pH=10. 2-iminothiolane hydrochloride (1) was 
added to the solution at a 2:1 molar ratio to the primary amines in chitosan oligosaccharides 
and stirred for 48 h under nitrogen to yield chitosan 4-thiobutylamidine conjugate 
(Chitosan-TBA) (2). The resulting thiol-modified chitosan oligosaccharides were 
precipitated by cold acetone and redissolved in water. This procedure was repeated twice to 
remove residual 2-iminothiolane.
1H NMR data of Chitosan-TBA (400 MHz, CD3OD, δ): 1.9 (C7: CHNHCOCH3), 2.1 
(CH2CH2CH2SH), 2.65 (CH2CH2CH2SH), 3.0 (C2: NH2CH(CH3)CH2NHCH), 3.2 
(CH2CH2CH2SH), 3.3–4.0 (C3, C4, C5, C6: OHCH, OCHCH(OH)CH(NH2)CH, 
OHCH2CH, OHCH2CH), 4.4 (C1: OCH(CHNH2)O).
3-Acetamido-4,4-dimethylthietan-2-one (NAP) was synthesized according to a previous 
report.[36] Briefly, acetic anhydride (5.9 mL, 63 mmol) was added dropwise over a period 
of 30 min to an ice-cooled solution of N-acetyl-D,L-penicillamine (4.0 g, 21 mmol) 
dissolved in anhydrous pyridine (10 mL) under N2. The solution was warmed to room 
temperature and stirred for 18 h. The stirring mixture was diluted with chloroform (150 mL), 
washed with 0.5 M hydrochloric acid (3 × 50 mL), and the organic layer dried over 
magnesium sulfate. The chloroform was concentrated under reduced pressure and the crude 
thiolactone product was precipitated and triturated in petroleum ether (100 mL), filtered, 
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rinsed with ether, and dried to yield a white crystalline solid (2.1 g). Tertiary thiol-modified 
chitosan oligosaccharides (Chitosan-NAP) (5) were synthesized by the reaction of 
thiolactone (i.e., 3-acetamido-4,4-dimethylthietan-2-one (NAP)) (4) with chitosan’s primary 
amines. First, the chitosan oligosaccharides (25 mg) were dissolved in aqueous solution (1 
mL) at pH 10. Thiolactone in 0.5 mL methanol (2:1 molar ratio to the primary amines on 
chitosan oligosaccharides) was then added to this solution. The solution was stirred for 48 h 
under nitrogen at room temperature. The resulting tertiary thiol-modified chitosan 
oligosaccharides were precipitated using cold acetone. The precipitate was then collected by 
centrifugation, redissolved in water and filtered to remove any undissolved material (e.g., 
NAP). The dissolution and precipitation cycle was repeated twice to remove residual 
thiolactone.
1H NMR data of Chitosan-NAP (400 MHz, CD3OD, δ): 1.3–1.4 ((CH3)C(CH)(SH)), 1.9–
2.1 (C7: CHNHCOCH3, CH3CONHCH), 3.0 (C2: NH2CH(CH3)CH2NHCH), 3.3–4.0 (C3, 
C4, C5, C6: OHCH, OCHCH(OH)CH(NH2)CH, OHCH2CH, OHCH2CH), 4.4 (C1: 
OCH(CHNH2)O).
Synthesis of Fluorescently-Labeled Chitosan Oligosaccharides
Fluorescently-labeled chitosan oligosaccharides were prepared following a procedure 
outlined in a previous report.[37] Briefly, chitosan oligosaccharides (50 mg) were dissolved 
in water (2 mL) at pH 9.0. Rhodamine B isothiocyanate (RITC) was added to the solution in 
a 1:100 molar ratio of RITC to the primary amine of the chitosan oligosaccharides, prior to 
the thiol-modification. The solution was stirred at room temperature for 3 d in the dark. 
Subsequent dialysis and lyophilization yielded the RITC-labeled chitosan oligosaccharides.
Ellman’s Assay
A solution of 2 mM 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB) in 50 mM sodium acetate 
was prepared and refrigerated until use. Chitosan samples were dissolved in water (0.4 
mg/mL) and diluted to 3 different concentrations (1:5, 1:10, 1:20). For the assay, 10 μL of 
the thiolated chitosan sample was incubated with 50 μL of the DTNB sodium acetate 
solution, 840 μL of ultrapure H2O, and 100 μL of Tris buffer (1 M, pH 8.0) for 5 min at 
37 °C. The optical density of this solution was measured at 412 nm. The absorbance value 
for each chitosan concentration was divided by the extinction coefficient of the DTNB 
mixed disulfide complex (13,600 M−1cm−1) to determine the concentration of thiol in 
solution. Thiol concentration was divided by the mass of chitosan in solution to obtain moles 
of thiol/mg chitosan.
Nitrosation of Thiol-Modified Chitosan Oligosaccharides
Thiol-modified chitosan oligosaccharides (25 mg) were dissolved in 5 M hydrochloric acid 
(1 mL) and methanol (2 mL). An aqueous solution (1 mL) containing sodium nitrite (5 × 
molar excess to thiol) and diethylenetriamine pentaacetic acid (DTPA) (500 μM) was then 
added dropwise. The mixture was stirred for 2 h in the dark and on ice before being cooled 
in the freezer (−20 °C) overnight. The resulting nitrosated chitosan oligosaccharides were 
collected by precipitation in cold acetone and isolation via centrifugation. The dissolution 
and precipitation cycle was repeated twice to remove residual salt. The nitrosated chitosan 
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oligosaccharides were then dried under vaccum at room temperature for 30 min and stored at 
−20 °C for future use.
Characterization of NO Release from S-Nitrosothiol-Modified Chitosan Oligosaccharides
S-nitrosothiol-functionalized chitosan oligosaccharides were added to deoxygenated 500 μM 
DTPA supplemented phosphate buffered saline (PBS; 30 mL) or regular PBS at 37 °C. 
Nitrogen was bubbled through the solution at a flow rate of 70 mL/min to carry the liberated 
NO to the analyzer. Additional nitrogen flow was supplied to the flask to match the 
collection rate of the instrument at 200 mL/min. The real-time NO-release profiles triggered 
by copper (50 mg/mL CuBr2), heat (37 °C, shielded from light), or light (37 °C, 200 W, 15 
cm above the reaction flask) were recorded. Chemiluminescence data for the NO-releasing 
chitosan oligosaccharides were represented as maximum NO flux ([NO]max, ppb/mg), total 
amount of NO release (t[NO], μmol NO/mg of secondary amine-functionalized chitosan 
oligosaccharides), and half-life (t1/2, h) under the different conditions.[8, 38] Total NO 
storage of the S-nitrosothiol-modified chitosan oligosaccharides was determined using the 
Griess assay. For this assay, chitosan oligosaccharides (2 mg) were dissolved in PBS (10 
mL) and exposed to light (200 W, 3 cm above the samples) for one week. The resulting 
solution was subjected to the Griess assay to determine total NO storage.
Bactericidal Assays against Planktonic Pseudomonas aeruginosa
P. aeruginosa bacterial cultures were grown from a frozen (−80 °C) stock overnight in tryptic 
soy broth (TSB) at 37 °C. A 500 μL aliquot of the resulting suspension was added into 50 
mL fresh TSB and incubated at 37 °C for ~2 h until the concentration reached ~1×108 
colony forming units (CFU)/mL, as confirmed by the OD600, replicate plating and 
enumeration on nutrient agar. Plating the bacterial suspension on TSA and incubating it at 
37 °C overnight was used to create a working bacterial stock. The tryptic soy agar (TSA) 
bacterial stocks were prepared weekly and stored at 4 °C. For bactericidal assays, colonies 
of P. aeruginosa were taken from the TSA plate, dispersed in 3 mL TSB, and incubated at 
37 °C overnight. A 500 μL aliquot of culture was added to 50 mL fresh TSB and incubated 
to a concentration of ~1×108 CFU/mL. The bacteria were collected by centrifugation, 
resuspended in PBS supplemented with 1 wt% glucose and 0.5 v/v% TSB, and diluted to 
~1×106 CFU/mL. The bactericidal efficacy of NO-releasing chitosan oligosaccharides 
against P. aeruginosa was evaluated by incubating the bacteria suspension with NO-releasing 
chitosan oligosaccharides at 37 °C. After 4 h of exposure, 100 μL aliquots of the bacterial 
suspensions were removed, diluted 10-fold in PBS, plated on TSA, and incubated overnight 
at 37 °C. The minimum concentration of NO-releasing chitosan oligosaccharides and 
ascorbic acid that resulted in a 4-log reduction of bacterial viability was defined as the 
minimum bactericidal concentration (MBC) for planktonic studies.
The checkerboard method was employed to determine the antibacterial efficacy of ascorbic 
acid and NO-releasing chitosan oligosaccharides in combination. Briefly, bacteria at a final 
innoculum concentration of 1 × 106 CFU/mL were incubated with an array of ascorbic acid 
and NO-releasing chitosan oligosaccharide concentrations for 4 h at 37 °C. The fractional 
bactericidal concentration index at 4 h was calculated using Equation 1, where MBCA and 
MBCB are MBC values determined for agents A and B, respectively, in a single-agent assay; 
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and MBCAB and MBCBA are the concentrations of agent A and B that constituted the 




P. aeruginosa was cultured in TSB to a concentration of ~1 × 108 CFU/mL, collected via 
centrifugation (3645 × g for 10 min), resuspended in sterile PBS, and adjusted to ~1 × 106 
CFU/mL. Aliquots of the bacteria solution were incubated in a glass bottom confocal dish 
for 1.5 h at 37 °C. A Zeiss 510 Meta inverted laser scanning confocal microscope with a 543 
nm HeNe excitation laser and a LP 585 nm filter was used to obtain fluorescence images of 
the rhodamine B isothiocyanate (RITC)-modified chitosan oligosaccharides. A 1.2 
numerical aperture C-apochromat water immersion lens with a 40× objective was used to 
collect both bright field and fluorescence images. Solutions of RITC-labeled NO-releasing 
chitosan oligosaccharides in PBS (1.5 mL) were added to the bacteria solution (1.5 mL) in 
the glass confocal dish to achieve a final concentration of 150 μg/mL. Images were collected 
after 1 h incubation to characterize the association of the chitosan oligosaccharides with P. 
aeruginosa.
In Vitro Cytotoxicity
L929 mouse fibroblasts were grown in DMEM supplemented with 10% v/v fetal bovine 
serum (FBS) and 1 wt% penicillin/streptomycin, and incubated in 5% v/v CO2 under 
humidified conditions at 37 °C. After reaching confluency (80%), the cells were trypsinized, 
seeded onto tissue-culture treated polystyrene 96-well plates at a density of 3×104 cells/mL, 
and incubated for 48 h at 37 °C. The supernatant was then aspirated prior to adding fresh 
DMEM (200 μL) with NO-releasing/control chitosan oligosaccharides or ascorbic acid 
solution in PBS (50 μL) to each well. After incubation at 37 °C for 24 h, the supernatant was 
aspirated, and a mixture of DMEM/MTS/PMS (105/20/1, v/v/v) (120 μL) was added to each 
well. The absorbance of the resulting colored solution after 1.5 h incubation at 37 °C was 
quantified at 490 nm using a Thermoscientific Multiskan EX plate reader (Thermo Fischer 
Scientific, Inc., Waltham, MA). The mixture of DMEM/MTS/PMS and untreated cells were 




All experimental measurements were repeated at least three times to calculate the standard 
deviation for each data point.
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Thiol-modified chitosan has attracted much attention for drug delivery applications due to 
their enhanced mucoadhesive and paracellular junction permeation properties.[39–41] 
Common synthetic routes for preparing thiol-modified chitosans include functionalization 
by L-cysteine, thioglycolic acid, and 2-iminothiolane, with the last being most attractive as 
no catalyst is required.[35] Due to increased reactivity of 2-iminothiolane at high pH, the 
modification efficiency of primary amines would likely to improve with increasing reaction 
solution pH. Unfortunately, chitosan polysaccharides are only soluble in acidic conditions, 
resulting in inherently low thiol modification efficiency.[35] In contrast, chitosan 
oligosaccharides exhibit excellent solubility in basic conditions, allowing more efficient 
primary amines functionalization. In this study, chitosan oligosaccharides were synthesized 
by oxidative degradation. The molecular weight (Mw) was calculated to be 5370 by the 
classic Mark-Houwink equation ([η] = 1.81×10−3 M0.93),[34] with a nitrogen content of 6.3 
± 0.2 wt% as determined by elemental analysis. Considering the deacetylation degree of 
~80%, these chitosan oligosaccharides contain ~4 μmol primary amines/mg chitosan, which 
was then used to calculate the 2-iminothiolane and NAP needed for the synthesis of thiol-
modified chitosan oligosaccharides.
Synthesis of Thiol-Modified Chitosan Oligosaccharides
Chitosan oligosaccharides were dissolved in aqueous solution (pH 10) and reacted with 2-
iminothiolane as shown in Scheme 1. NMR was used to characterize the resulting primary 
thiol-modified chitosan oligosaccharides (Chitosan-TBA). A distinct resonance at 2.65 ppm 
was apparent, corresponding to the methylene protons adjacent to the sulfhydryl group of the 
products. Tertiary thiol-functionalized chitosan oligosaccharides (Chitosan-NAP) were 
synthesized by reaction of the chitosan primary amine with thiolactone (NAP) via a ring 
opening reaction. The associated NMR data revealed a resonance at ~1.3 ppm indicative of 
NAP’s methyl groups. The thiol content of the Chitosan-TBA and Chitosan-NAP as 
determined with Ellman’s assay was 1.1 ± 0.1 and 1.2 ± 0.1 μmol/mg, respectively.
Nitric Oxide-Release Properties
Thiol-modified chitosan oligosaccharides (e.g., Chitosan-TBA, Chitosan-NAP) were 
nitrosated with sodium nitrite in 5 M HCl to store NO.[42] S-nitrosothiol formation was 
confirmed by the red and green color of the resulting primary (Chitosan-TBA) and tertiary 
S-nitrosothiol-modified (Chitosan-NAP) chitosan oligosaccharides, respectively. The total 
NO storage was assessed indirectly using the Griess assay. Briefly, chitosan oligosaccharides 
were dissolved in PBS and exposed to light for a week, allowing for complete 
decomposition. The NO totals for Chitosan-TBA-NO and Chitosan-NAP-NO were 300 
± 14 and 350 ± 25 nmol/mg, respectively. These results were confirmed using 
chemiluminescence for NO release triggered by copper.[43] As expected, copper-mediated 
NO donor decomposition is characterized by more rapid NO release kinetics compared to 
heat and light. Within the first few minutes, the majority of S-nitrosothiols were 
decomposed, with Chitosan-TBA-NO and Chitosan-NAP-NO releasing ~90 and 85% of 
their total payloads at 0.1 h, respectively. Although copper-mediated NO release is unlikely 
to be clinically useful as blood/tissue does not contain much free copper ions, the rapid NO 
Lu et al. Page 7













release facilitates prompt measurement of total NO storage, particularly for S-nitrosothiol 
NO donors with slow NO-release kinetics under physiological conditions (37 °C, pH=7.4).
Photolysis of Chitosan-TBA-NO and Chitosan-NAP-NO was characterized using a broad-
spectrum white light source to investigate a potentially more clinically relevant NO-release 
trigger. As shown in Table 1, the total NO release after 24 h of irradiation was ~75 nmol/mg, 
~20% of the total available payloads. The NO release data indicated that Chitosan-TBA-
NO release NO slower than Chitosan-NAP-NO (Figure 2, Table 1). These results are 
somewhat surprising when considering the S-nitrosothiol structure alone. Indeed, the 
primary S-nitrosothiol systems (Chitosan-TBA-NO) would be expected to release NO 
faster, not slower. However, the behavior is similar to previously reported S-nitrosothiol-
modified dendrimers,[44] where increased NO donor stability of Chitosan-TBA-NO is 
likely the result of a more compact structure and less steric hindrance around the S-
nitrosothiol groups. This phenomenon may result in a greater microviscosity inside the 
chitosan oligosaccharides and increased frequency of geminate radical pair recombination 
(caging effect), consequently slowing the rates of NO release.[44]
Thermal decomposition of S-nitrosothiols at 37 °C is of greatest interest for biomedical 
applications where light irradiation is not applicable. Similar to photolytic S-nitrosothiol 
decomposition, thermal irradiation leads to homolytic cleavage of the S-N bond, yielding a 
thiyl radical and NO.[29] The thermal decomposition of Chitosan-TBA-NO and Chitosan-
NAP-NO was characterized in both DTPA-supplemented and regular PBS at 37 °C, shielded 
from light (Figure 3).
To eliminate effects from trace copper ion, DTPA was added to PBS as a chelator. As above 
for photolytic decomposition, primary S-nitrosothiol-modified chitosan oligosaccharides 
(Chitosan-TBA-NO) exhibited slower NO release than the tertiary system (Chitosan-NAP-
NO). The caging effect, resulting in greater geminate radical pair recombination, clearly 
impacts both light and thermal NO donor breakdown for S-nitrosothiol-modified chitosan. 
The total NO release was ~30 and 13 nmol/mg for Chitosan-NAP-NO and Chitosan-TBA-
NO, respectively. While important for understanding the NO release, DTPA-supplemented 
PBS is not relevant to clinical applications (e.g., intravenous injection, wound wash, and 
pulmonary delivery).[45] The NO release of S-nitrosothiol-modified chitosan 
oligosaccharides in regular PBS with and without ascorbic acid was thus investigated to 
ascertain the influence of a) normal PBS and b) a common reducing agent in blood of 
importance. Ascorbic acid decomposes S-nitrosothiols via two distinct pathways.[32] At low 
concentrations, ascorbate reduces Cu2+ to generate Cu+, which in turn decomposes RSNO to 
disulfide and NO.[46] Since copper ion is key, the use of a copper ion chelator results in 
reduced NO release. At higher concentrations, ascorbic acid can also reduce S-nitrosothiol 
NO donors directly, yielding thiol and O-nitrosoascorbate, the latter decomposing into 
dehydroascorbic acid and NO by a free-radical pathway.[32] In contrast to the first 
mechanism, this reaction is not copper ion dependent.[32] Our goal was to study the effect 
of ascorbic acid on NO-release kinetics for S-nitrosothiol-modified chitosan 
oligosaccharides in PBS. As shown in Table 2, both Chitosan-TBA-NO and Chitosan-
NAP-NO released greater amount of NO in regular PBS compared to DTPA-supplemented 
PBS due to the copper-mediated NO release. In regular PBS, trace Cu2+ (i.e., 640±50 
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ppb/mL by inductively coupled plasma) was reduced by residual thiolate ions on the 
chitosan oligosaccharides to yield Cu+ and more NO than the thermal decomposition in 
DTPA-supplemented PBS. Chitosan-NAP-NO released ~240 nmol NO/mg in regular PBS, 
significantly greater than the ~78 nmol NO/mg by thermal decomposition alone. The NO 
release half-life was ~0.82 and 0.52 h for Chitosan-TBA-NO and Chitosan-NAP-NO, 
respectively, a significantly faster overall release than that observed with DTPA-
supplemented PBS (Table 2). The Chitosan-TBA-NO also exhibited slower NO release due 
to the caging effect, as described above.
Nitric oxide release in PBS as a function of ascorbic acid concentrations (i.e., 0.1–0.5 
mg/mL) was characterized to better understand the role of this reducing agent on NO-release 
kinetics. Enhanced S-nitrosothiol decomposition was observed in the presence of ascorbic 
acid as indicated by shorter half-life and greater maximum NO flux (Table 2). The half-life 
of NO release from Chitosan-NAP-NO was ~0.52, 0.10 and 0.07 h at 0, 0.1 and 0.5 mg/mL 
ascorbic acid, respectively. Compared to the copper ion-mediated NO release in regular 
PBS, ascorbic acid proved to be a stronger reducing agent than thiolate ions, leading to 
faster S-nitrosothiol NO donor decomposition.[32] Along with the copper ion-mediated NO 
release, the direct reduction of S-nitrosothiol NO donor by ascorbic acid may also contribute 
to S-nitrosothiol decomposition.[32] The NO release of Chitosan-NAP-NO and Chitosan-
TBA-NO at different concentrations of ascorbic acid (i.e., 0.1 and 0.5 mg/mL) was thus 
characterized in DTPA-supplemented PBS. As shown in Figure 4, the use of copper ion 
chelator had little impact on the total NO release in 0.1 and 0.5 mg/mL ascorbic acid, 
indicating the presence of S-nitrosothiol decomposition via direct reduction by ascorbic 
acid. Of note, the NO release in DTPA-supplemented PBS did show lower maximum NO 
flux and slower decay compared to the NO-release behavior in regular PBS. This difference 
in S-nitrosothiol breakdown to NO indicates that both S-nitrosothiol decomposition 
pathways play a role in NO release from S-nitrosothiol-modified chitosan oligosaccharides 
by ascorbic acid in regular PBS.
Bactericidal studies
Nitric oxide releasing materials (e.g., silica particles, dendrimer) have been demonstrated to 
be effective at killing bacteria.[9, 47] However, their lack of biodegradability may be 
problematic for clinical applications. In this study, control and NO-releasing chitosan 
oligosaccharides (e.g., Chitosan-TBA-NO, Chitosan-NAP-NO) were exposed to Gram– 
negative P. aeruginosa, a pathogen involved in infections associated with burn wounds and 
cystic fibrosis, to evaluate their ability to kill bacteria,.[48, 49] Bacterial viability assays 
were performed in nutrient conditions to determine the concentration of chitosan required to 
reduce bacteria viability in 4 h by 4 logs (i.e., 99.99% killing), which hereafter is referred to 
as the minimum bactericidal concentration or MBC. Given that ascorbic acid is bactericidal 
against P. aeruginosa with synergistic efficacy depending on the antibiotic,[31, 50] we also 
evaluated the combination of S-nitrosothiol-modified chitosan oligosaccharides and ascorbic 
acid. Both the MBC for the NO-releasing chitosan oligosaccharides and the fractional 
bactericidal concentration index (FBC) of NO-releasing chitosan at different concentrations 
of ascorbic acid (i.e., 0.1 and 0.5 mg/mL) are provided in Table 3. The MBC for ascorbic 
acid alone was 2.5 mg/mL. Control thiol-modified chitosan oligosaccharides with ascorbic 
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acid at 0.1 and 0.5 mg/mL elicited no significant reduction (<1 log) in bacterial viability at 
the MBCs for their NO-releasing counterparts. Of note, 0.1 and 0.5 mg/mL ascorbic acid in 
the PBS (pH=7.4) slightly lowered the pH to 7.3 and 6.8, respectively. As shown in Table 3, 
Chitosan-TBA-NO proved more effective against P. aeruginosa than Chitosan-NAP-NO 
despite the lower total NO storage. This effect is likely the result of better association of 
Chitosan-TBA-NO with bacterial membrane.
Indeed, Chitosan-TBA-NO is more positively charged due to the presence of amine on the 
TBA unit. It would be thus expected to associate more extensively with the negatively 
charged outer bacterial membrane. To confirm this hypothesis, confocal microscopy was 
used to characterize the association of both Chitosan-TBA-NO and Chitosan-NAP-NO 
with P. aeruginosa. As shown in Figure 5, bacteria incubated with Chitosan-TBA-NO 
exhibited more red RITC fluorescence, indicating greater association with the bacterial 
membrane compared to Chitosan-NAP-NO. The bactericidal efficacy was found to be 
synergistic for ascorbic acid (0.1 mg/mL) and Chitosan-NAP-NO (FBC≤0.5). While the 
combination of Chitosan-TBA-NO and ascorbic acid resulted in a FBC=0.51, a value some 
consider moderately synergistic,[51] it was significantly greater than the additive effect 
(FBC=1) of single antibacterial agents (i.e., ascorbic acid or Chitosan-TBA-NO alone). 
These results demonstrate the benefit of ascorbic acid as a NO-release trigger for S-
nitrosothiol-modified chitosan oligosaccharides in bacterial killing. The enhanced 
bactericidal efficacy is likely the result of a greater initial NO level induced by the ascorbic 
acid, corroborating previous observations.[10]
Cytotoxicity to Murine Fibroblasts
The benefit of chitosan as an NO-releasing vehicle includes its non-toxic nature.[28] 
However, the effects of both NO and ascorbic acid on mammalian cells are unknown. Thus, 
the cytotoxicity of ascorbic acid, control and NO-releasing chitosan oligosaccharides were 
evaluated against L929 mouse fibroblast cells.
Normalized cell viabilities in the presence of ascorbic acid, and control and NO-releasing 
chitosan oligosaccharides after 24 h incubation are shown in Figure 6. Ascorbic acid at both 
0.1 and 0.5 mg/mL elicited minimum toxicity (~15%) to the L929 fibroblast cells. Of note, 
significantly reduced cell death for Chitosan-TBA-NO was observed compared to 
Chitosan-NAP-NO. A key difference between these two NO-release materials is the initial 
NO flux. Nitric oxide is a well known bifunctional regulator of apoptosis.[52] High dose of 
NO can interact with superoxide ions to produce peroxynitrite and induce apoptotic DNA 
fragmentation and p53-dependent apoptosis. In contrast, low doses of NO inhibit apoptosis 
via multiple mechanisms (e.g., cGMP-mediated interruption of apoptotic signaling and 
direct inhibition of caspase activity).[52] This bifunctional role of NO may likely explain the 
greater cytotoxicity of Chitosan-NAP-NO over Chitosan-TBA-NO. In this regard, 
Chitosan-TBA-NO may serve as a more suitable antibacterial agent for biomedical 
applications such as wound healing due to being more tolerable to mammalian cells.
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A new class of NO-releasing chitosan oligosaccharides with tunable NO-release kinetics is 
described using S-nitrosothiols NO donors and ascorbic acid. The combination of S-
nitrosothiol-modified chitosan oligosaccharides and ascorbic acid allows for synergistic 
bactericidal action against P. aerugionsa. At concentrations eliciting a 4-log reduction in 
bacterial viability under nutrient condition, primary S-nitrosothiol-modified chitosan 
oligosaccharides showed minimal toxicity against L929 mouse fibroblast cells. This study 
demonstrates the potential of S-nitrosothiol-modified chitosan oligosaccharides as 
antibacterial agents. The biodegradability of chitosan makes this NO-releasing material a 
viable therapeutic candidate for a range of biomedical applications including chronic 
wounds, nasal infections, and cystic fibrosis. Experiments are underway to evaluate the 
biocidal efficacy of these materials against a broad spectrum of bacteria strains including 
Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and cystic fibrosis-
related P. aeruginosa strains (e.g., mucoid/alginate-producing strains).
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Nitric oxide release from Chitosan-TBA-NO (solid square) and Chitosan-NAP-NO (open 
square) in 50 mg/mL CuBr2 aqueous solution at 37 °C as measured by chemiluminescence.
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Nitric oxide-release profiles for Chitosan-TBA (open square) and Chitosan-NAP (solid 
square) under light irradiation (200 W, 15 cm above) as measured by chemiluminescence. 
Inset: total NO release with time (nmol/mg).
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Nitric oxide-release profiles for Chitosan-TBA (open square) and Chitosan-NAP (solid 
square) in DTPA-supplemented PBS at 37 °C shielded from light as determined using 
chemiluminescence. Inset: total NO release with time (nmol/mg).
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Nitric oxide-release properties for (A) Chitosan-NAP-NO and (B) Chitosan-TBA-NO in 
0.1 (square) and 0.5 (circle) mg/mL ascorbic acid with (open) and without (solid) DTPA. 
Inset: total NO release with time (nmol/mg).
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Bright field/fluorescent overlay images (A and C) and fluorescent images (B and D) of 
RITC-label NO-releasing chitosan oligosacchrides association with planktonic P. 
aeruginosa. A) and B) Chitosan-NAP-NO; C) and D) Chitosan-TBA-NO. Scale bar 10 μm.
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Cytotoxicity of ascorbic acid (AA) at 0.1 and 0.5 mg/mL (grey), and NO-releasing (black) 
and control (white) chitosan oligosaccharides in 0.1 and 0.5 mg/mL ascorbic acid solutions 
against L929 mouse fibroblast cells at 24 h.
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Synthesis of S-nitrosothiol-modified chitosan oligosaccharides. 1) 2-iminothiolane; 2) 
Chitosan-TBA; 3) Chitosan-TBA–NO; 4) Thiolactone (NAP); 5) Chitosan-NAP; 6) 
Chitosan-NAP-NO.
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Table 3
Minimum bactericidal concentration (MBC) and fractional bactericidal concentration index (FBC) for S-










0 15 – 30 –
0.1 7 0.51 10 0.37
0.5 5 0.53 10 0.53
a
concentration of S-nitrosothiol-modified chitosan for 4-log reduction in P. aeruginosa viability. Each parameter was analyzed with multiple 
replicates (n=3).
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